NCT06533644
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Minor Trial sites expanded: 19 → 23 locationsv11
- Notable Eligibility criteria expanded, about 223 words
- Primary and study completion pushed from Dec 14, 2027 to Apr 14, 2028
- Enrollment increased: 70 → 91 participants
- Trial sites expanded: 9 → 19 locations
- Minor Study sites: 5 to 9v9
- Minor Study sites revised (5)v8
Show 6 earlier versionsHide 6 earlier versions
- Minor Study sites: 3 to 5
- Start date changed from estimate of May 2025 to May 29, 2025
- Notable Start date: Mar 2025 to May 2025
- Study sites: 2 to 3
Notable Phase: Phase 1 to Phase 2v5 Show 6 more changesShow less
- Enrollment target: 28 to 70
- Eligibility criteria expanded, about 38 words
- Primary endpoints: 4 to 5
- Interventions: SV-102 (Drug) to Partial Oncolysis (Procedure), SV-102 (Drug)
- Secondary endpoints revised (16)
- Study arms: 4 to 5
- Minor Study sites: 1 to 2
- Start date: Jan 2025 to Mar 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Nov 2024 to Jan 2025
- Study sites: 0 to 1
- Notable Start date: Sep 15, 2024 to Nov 2024
- Study title revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (16)
Show 11 moreShow less
Arms and interventions
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 1.
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 2.
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 3.
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, dose level selected from Part 1.
Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, dose level selected from Part 1.
Procedures: Partial Oncolysis
Drugs: SV-102
Sites
23 sites in 1 country